Equillium Closes $20M Milestone Tranche After First EQ504 Patient Dosed
EQ sits 71% above its 52-week low of $0.756 on light trading volume (0.3× avg).
Summary
Equillium closed the $20 million milestone tranche of its 2025 private placement after dosing its first EQ504 patient, bringing total placement proceeds to about $50 million and funding operations into 2029. Pricing was $0.57 per share, well below today's $1.29, and the shares carry resale registration rights.
Key Events · Financing and Capital Events · EQ
-
Milestone Tranche Closes at $20 Million
Equillium issued 14,957,260 shares at $0.57 and 20,130,457 pre-funded warrants at $0.5669, for aggregate gross proceeds of $20.0 million.
-
Total Placement Now ~$50 Million
With this closing, total proceeds under the August 2025 private placement reach approximately $50 million, and cash is expected to fund planned operations into 2029.
-
Price Threshold Waived by Investors
The requisite investors waived the $2.50 weighted-average price condition and consented to closing on the Milestone Event Date of October 26, 2026.
-
Resale Registration Due Within 30 Days
Equillium must file a resale registration statement within 30 days of the closing, with cash penalties if registration is delayed or fails.
Analysis · EQ · Life Sciences
The trigger investors were waiting on has arrived: Equillium pulled down the second $20 million tranche of its August 2025 private placement after dosing the first EQ504 subject in Australia. The cash is real and extends the runway into 2029, but it was raised at $0.57 per share against today's $1.29, leaving the new buyers with a large paper gain and the stock with a resale-registration overhang. Because the pre-funded warrants (20.1M at a $0.0001 strike) are effectively already shares, the economic dilution runs larger than the 14.96M common shares alone imply.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EQ was trading at $1.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $79.3M. The 52-week trading range was $0.76 to $3.54. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.